Authors

Peter Riedell, MD, is an associate professor of medicine in the Section of Hematology/Oncology at the University of Chicago.

Latest:

Overcoming Barriers and Improving CAR T Care in Academic and Community Settings

Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.

Bonnie J. Dirr, APRN

Latest:

Monitoring and Follow-Up of Patients with Chronic GVHD

The panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.

Sponsored Content by Pfizer

Rima Patel, MD

Latest:

Dr. Patel on the Association Between Ki-67 and Race in Early Breast Cancer

Rima Patel, MD, discusses the associations between the 21-gene oncotype DX recurrence score, Ki-67, and race in early-stage breast cancer.

Courtney Flaherty

Courtney Flaherty joined

Latest:

Dr Freedland on the Next Steps for Evaluating Enzalutamide in Prostate Cancer

Stephen J. Freedland, MD, discusses future avenues for research with enzalutamide in biochemically recurrent prostate cancer.

Laleh Melstrom, MD, MS

Latest:

Dr Melstrom on Challenges Implementing Widespread Molecular Testing in GI Cancer

Laleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.

Mridula George, MD

Latest:

Patient Selection and Implementation Strategies for MRD Testing

Panelists emphasize that as circulating tumor DNA (ctDNA) testing becomes more integrated into clinical practice, careful interpretation, tailored testing schedules, and ongoing provider education are key to its effective use in personalized breast cancer care.

Ali Amjad, MD

Latest:

FDA Approvals of Immunotherapy in Gynecology Oncology

In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.

Thach-Giao Truong, MD

Latest:

Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ Melanoma

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, is a consultant hematologist at King's College Hospital NHS Foundation Trust in London.

Latest:

Addressing Further Unmet Needs in PNH

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, discuss unmet needs to address in the management of PNH.

Balazs Halmos, MD, MS

Balazs Halmos, MD, is the director of Thoracic Oncology and the director of Clinical Cancer Genomics at Albert Einstein College of Medicine, Montefiore Einstein

Latest:

Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS

Dr Halmos discusses the VISION trial, the significance of MET exon 14 skipping mutations in NSCLC, and the clinical utility of tepotinib in this disease.

Martin Reck, MD, PhD

Latest:

Five-Year Outcomes With First-Line (1L) Nivolumab + Ipilimumab + Chemotherapy (N + I + C) vs C in Patients (pts) With Metastatic NSCLC (mNSCLC) in CheckMate 9LA

Dr. Martin Reck presents the five year update of CheckMate 9LA (NCT03215706) and exploratory analysis of efficacy in patients who discontinued treatment due to treatment related adverse events in patients with metastatic non-small lung cancer.

Fenghuang Zhan, MD, PhD

Latest:

Charting a Path for the Integration of Immunotherapy in the Treatment of Multiple Myeloma

Fenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.

Jacqueline Barrientos, MD, MS

Latest:

Expert Insights into Investigation Therapies for CLL

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Lucy Bailey, CRNP

Latest:

Evolving First-Line Standards and the Foundation of Follicular Lymphoma Care

This segment outlines how clinicians today approach initial management, recognizing that improved survival and expanding treatment choices have dramatically changed the patient journey. As Mehta and Bailey note, frontline success does not eliminate the likelihood of relapse, making it essential to anticipate how early decisions may influence subsequent therapeutic sequencing.

Jose A. Karam, MD, FACS

Latest:

Dr Karam on Key Kidney Cancer Takeaways From the 2023 IKCS

Jose A. Karam, MD, FACS, discusses key takeaways from the 2023 International Kidney Cancer Symposium.

Steven Park, MD

Latest:

Dr Park on the Rationale for the SYMPHONY-1 Trial in Relapsed/Refractory FL

Steven Park, MD, discusses the mechanism of action of tazemetostat and the rationale for the phase 3 SYMPHONY-1 trial in patients with relapsed follicular lymphoma.

J. Marcus Downs, MD, FACS, FASCRS

Latest:

Transforming Cancer Care Through Data: How Texas Colon & Rectal Specialists Enhances Outcomes, Experiences, and Efficiency

How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome.

Olalekan O. Oluwole, MD, MPH

Olalekan Oluwole, MD, MPH, is an associate professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center.

Latest:

Dr Oluwole on the Importance of Assessing the Onset and Incidence of Axi-Cel–Related Neurotoxicity in R/R DLBCL

Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.

Michael R. Migden, MD

Latest:

Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.